0 0 0 0 0 0 0 0
Sign Up Today X
Thanks for submitting the form.
Stockreport

Allogene Therapeutics Teases April ALPHA3 Futility Data, Details Autoimmune CAR-T Program at TD Cowen [Yahoo! Finance]

Allogene Therapeutics, Inc. (ALLO)  More Company Research Source: Yahoo! Finance
Last allogene therapeutics, inc. earnings: 2/27 04:30 am Check Earnings Report
based on MRD clearance in 24 patients , with a prespecified bar of an absolute 25–30% MRD clearance improvement for cema-cel versus observation; the randomized ~220-patient study uses event-free survival as the primary endpoint. Management says its "Allogene XL" allogeneic CAR-T can be manufactured at “biologic-like” scale (~ 20,000–60,000 doses/year ) with estimated cost of goods of $10,000–$20,000 per dose, and frames a commercial opportunity of ~ MRD-positive/insufficiently treated patients in the U.S. and Europe (~ $5 billion TAM) with potential peak sales well over $2 billion The autoimmune program ALLO-329 is a dual CD19/CD70 "Dagger" allogeneic CAR-T designed to enable lighter or no lymphodepletion (starting at 20M cells with Cy-only and no-LD cohorts), with initial proof-of-concept and biomarker readouts expected in June 2026 Interested in Allogene Therapeutics, Inc.? Here are five stocks we like better. 3 Stocks With Sky-High Short Interest Levels Allogene Therapeut [Read more]
IMPACT SNAPSHOT EVENT TIME: ALLO
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
ALLO alerts
from News Quantified
ALLO
NEWS
ALLO
Earnings
ALLO
Analyst Actions
ALLO
SEC Filings
Stockreport

Allogene Therapeutics Teases April ALPHA3 Futility Data, Details Autoimmune CAR-T Program at TD Cowen [Yahoo! Finance]

Allogene Therapeutics, Inc.  (ALLO) 
More Company Research Source: Yahoo! Finance
Last allogene therapeutics, inc. earnings: 2/27 04:30 am Check Earnings Report
based on MRD clearance in 24 patients , with a prespecified bar of an absolute 25–30% MRD clearance improvement for cema-cel versus observation; the randomized ~220-patient study uses event-free survival as the primary endpoint. Management says its "Allogene XL" allogeneic CAR-T can be manufactured at “biologic-like” scale (~ 20,000–60,000 doses/year ) with estimated cost of goods of $10,000–$20,000 per dose, and frames a commercial opportunity of ~ MRD-positive/insufficiently treated patients in the U.S. and Europe (~ $5 billion TAM) with potential peak sales well over $2 billion The autoimmune program ALLO-329 is a dual CD19/CD70 "Dagger" allogeneic CAR-T designed to enable lighter or no lymphodepletion (starting at 20M cells with Cy-only and no-LD cohorts), with initial proof-of-concept and biomarker readouts expected in June 2026 Interested in Allogene Therapeutics, Inc.? Here are five stocks we like better. 3 Stocks With Sky-High Short Interest Levels Allogene Therapeut [Read more]
IMPACT SNAPSHOT
EVENT TIME:
ALLO
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Don't Miss Out On The Next BIG Stock Move
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS